

Edgar Filing: NANOBAC PHARMACEUTICALS INC - Form NT 10-Q

NANOBAC PHARMACEUTICALS INC  
Form NT 10-Q  
November 14, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 12b-25

Commission File Number 0-24696

NOTIFICATION OF LATE FILING

(Check One):     Form 10-K         Form 11-K         Form 20-F  
                   Form 10-Q         Form N-SAR

For Period Ended: September 30, 2007

Transition Report on Form 10-K

Transition Report on Form 20-F

Transition Report on Form 11-K

Transition Report on Form 10-Q

Transition Report on Form N-SAR

For the Transition Period Ended:

Read attached instruction sheet before preparing form. Please print or type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

PART I  
REGISTRANT INFORMATION

Nanobac Pharmaceuticals, Incorporated  
-----

Full Name of Registrant

Former Name if Applicable

4730 North Habana Avenue, Suite 205  
-----

Address of Principal Executive Office (Street and Number)  
Tampa, Florida 33614  
-----

City, State and Zip Code

PART II  
RULE 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

Edgar Filing: NANOBAC PHARMACEUTICALS INC - Form NT 10-Q

(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K or Form N-SAR, or portion [X] thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III  
NARRATIVE

State below in reasonable detail why the Form 10-K, 11-K, 20-F 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period. (Attach extra sheets if needed.)

The review of the Form 10-QSB for the period ending June 30, 2007 could not be completed within the prescribed time period by the Company's public accountants.

PART IV  
OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

John Stanton	(813)264-2241
-----	-----
(Name)	(Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).  Yes  No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  Yes  No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Nanobac Pharmaceuticals, Incorporated  
-----  
(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date November 14, 2007

By /s/John Stanton

-----  
John Stanton  
Chief Executive Officer